The one-two punch that guarantees success in Japan’s pharma market is a new drug and good people to execute its development and marketing. One without the other is like a kiss without a squeeze, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter.
Ever since Japan opened its doors to the West, it searched the world for the best technology and brought it home to make it better. New is better than old.
An every-day example is the absence of old cars on Tokyo’s streets. Also, it’s not easy to find a used car dealer. One never sees a garage sale and flea markets are rare except for antiques. Laundromats are scarce. Who wants to use a machine used by someone else?
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze